This inventor holds 3 USPTO granted patents. Top assignees: University of Illinois, California Institute of Technology, University of California. Active years: 2011-2016.
Company Filing History:
2 out of 2,421 
1 out of 4,624 
1 out of 15,988 
Years Active: 2011-2016
Title: Innovations by Senthil Radhakrishnan
Introduction
Senthil Radhakrishnan is a notable inventor based in Pasadena, California. He has made significant contributions to the field of cellular biology and apoptosis through his innovative patents. With a total of 3 patents, Radhakrishnan's work focuses on methods and compositions that enhance apoptosis in mammalian cells.
Latest Patents
Radhakrishnan's latest patents include groundbreaking methods for preventing induced synthesis of proteasomes in human cells. One of his notable inventions provides methods and compositions for inhibiting Nrf1 activity, which enhances apoptosis in mammalian cells. This process involves co-inhibiting Nrf1 activity and proteasome activity to achieve the desired effect. Another significant patent involves nucleoside compounds and methods of use, which detail how a nucleoside derivative can downregulate the expression of anti-apoptotic proteins, induce apoptosis, and inhibit angiogenesis in cells.
Career Highlights
Throughout his career, Radhakrishnan has worked with prestigious institutions such as the University of Illinois and the University of California. His research has contributed to a deeper understanding of cellular processes and potential therapeutic applications.
Collaborations
Radhakrishnan has collaborated with esteemed colleagues, including Andrei Gartel and Raymond J Deshaies. These partnerships have furthered his research and innovation in the field.
Conclusion
Senthil Radhakrishnan's contributions to the field of cellular biology through his patents demonstrate his commitment to advancing scientific knowledge. His innovative methods for enhancing apoptosis and inhibiting cellular processes have the potential to impact therapeutic strategies significantly.